Mon, May 12, 3:59 PM (42 days ago)
**The Greater Cannabis Company, Inc. (TGCI) - Q1 2025 Financial Summary** **Ticker: TGCI** **Financial Health & Performance:** - **Revenue:** No revenue was generated in Q1 2025, consistent with Q1 2024. - **Profit Margins:** The company reported a net loss of $103,511,000 in Q1 2025, compared to a net loss of $44,611,000 in Q1 2024. - **Cash Flow:** Operating cash flow was negative $11,155,000 in Q1 2025, an improvement from negative $37,536,000 in Q1 2024. - **Earnings Changes:** The net loss increased significantly due to a $57,920,000 loss on conversion of notes payable. - **Cash Position:** Cash decreased to $46,213,000 from $57,368,000 at the end of 2024. **Trends & Uncertainties:** - **Operational Focus:** TGCI is concentrating on developing and commercializing cannabinoid therapeutics, particularly for neuropsychiatric disorders. - **Funding Needs:** The company faces substantial doubt about its ability to continue as a going concern, requiring additional funding to sustain operations and development plans. - **Regulatory & Clinical:** The company awaits clinical data from Phase II trials to proceed with regulatory approvals, which are uncertain in timing and outcome. **Future Operations Impact:** - **Clinical Development:** TGCI plans to invest up to $1,000,000 over two years for clinical studies on its cannabinoid therapeutic. - **Strategic Shifts:** The company is exploring various investment and development opportunities in the cannabis sector. - **Financial Risks:** TGCI must secure additional financing to avoid substantial curtailment or cessation of operations, which could materially affect its business and shareholders.